Prevention treatment of obesity

TYPE OF DEVELOPMENT

Drug.

DESCRIPTION

This invention describes how the acute  downregulation in a gene expression in liver by the use of antisense oligonucleotides prevents and/or ameliorates obesity and the associated metabolic complications.

Increased prevalence of obesity has led to the rise in the development of metabolic diseases such as diabetes, insulin resistance, dyslipemia and liver disease. Nowadays, there is an urgent need of finding therapeutic targets for obesity and the associated co-morbidities.

This invention refers to the prevention and treatment of obesity and the associated metabolic disease through the dowregulation of the expression of a target gene, which mainly expresses in liver.

INDICATION

Treatment of diet induced obesity and the associated metabolic disease. 

NOVELTY/ADVANTAGE

• A single dose per week
• A single treatment for obesity and all the associated metabolic diseases.
• No liver damage has been reported

INFORMATION

• Reference: Metabolic Disease
• Research group: Lipids & Liver.
• Main researcher: Patricia Aspichueta Celaá.
• Contact: Knowledge/Technology Transfer Office, iproperty.otri@ehu.eus

IPR STATUS

• Patent application: EP19762826
• Priority date: 10/09/2018
• Applicant: University of the Basque Country (UPV/EHU)

COOPERATION GOAL

• Company interested in the license and sponsored reserarch.